Overview

A Study of TAS3351 in NSCLC Patients With EGFRmt

Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human, open label, Phase 1/2 study to investigate the safety and efficacy of TAS3351 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring an acquired C797S epidermal growth factor receptor (EGFR) mutation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Taiho Oncology, Inc.